NIHR Oxford Biomedical Research Centre

Enabling translational research through partnership

MENUMENU
  • About
    • About the NIHR Oxford Biomedical Research Centre
    • Activities during COVID-19
    • Strategic Partnership Board
    • Steering Committee
    • Promoting Equality, Diversity and Inclusion in Research
    • Current Vacancies
    • Contact Us
    • Stay in Touch
  • Research

        • Research Overview
        • Clinical Research Facility
        • 15 Research Themes

        • Cancer
        • Cardiovascular Medicine
        • Digital Health from Hospital to Home
        • Gene and Cell Therapy
        • Genomic Medicine
        • Imaging
        • Inflammation across Tissues
        • Life-saving Vaccines
        • Metabolic Experimental Medicine
        • Modernising Medical Microbiology and Big Infection Diagnostics
        • Musculoskeletal
        • Preventive Neurology
        • Respiratory Medicine
        • Surgical Innovation, Technology and Evaluation
        • Translational Data Science
  • Patient & Public Involvement
    • Getting involved with research
    • View and register for involvement opportunities
    • Patient & Public Groups
    • Patient and Public Involvement Advisory Group
    • Diversity in Research Group
    • Oxford Blood Group
    • Case Studies
    • PPIE Strategy
    • PPIE News
    • PPI Researcher Guidance
    • Researchers: Post a PPIE opportunity
  • Training Hub
    • Training Hub Overview
    • Clinical Academic Pathway
    • Internships
    • Preparatory Research Fellowships
    • Senior Research Fellowships
    • Research Training Bursaries
    • Doctoral Awards
    • Post-Doctoral Awards
    • Other funding
    • Leadership Training
    • Useful Links
    • Training and Education Resources
    • Upcoming Training Events & Courses
  • Industry
    • Collaborate with Oxford BRC
    • Who Do We Work With?
    • Events
    • Further Information and Additional Resources
    • Contacts for Industry
  • Videos
  • News
  • Events

News

You are here: Home > Surgical Innovation, Technology and Evaluation > Bioelectronic implant offers intelligent therapy to treat incontinence

Bioelectronic implant offers intelligent therapy to treat incontinence

1 February 2023 · Listed under Surgical Innovation, Technology and Evaluation

The first participants in a clinical trial of a bioelectrical therapy to treat incontinence have received their ‘smart’ bioelectronic implants.

Amber Therapeutics, a University of Oxford spin-out company developing intelligent bioelectrical therapies, applied the Picostim-DyNeuMo research system developed in collaboration with Bioinduction Ltd. The AURA-2 study represents the latest use of the Picostim-DyNeuMo research platform, which was first implanted at Oxford last year for the treatment of Parkinson’s-like multiple system atrophy.

The Picostim-DyNeuMo research system toolbox was developed as a general-purpose bioelectronic therapy development platform. For the AURA-2 study, leads are placed along the pudendal nerve and the implanted system provides stimulation patterns under the control of the research participant.

This research is supported by the NIHR Oxford Biomedical Research Centre (BRC). This kind of neuromodulation is an important area of research in the BRC’s new Surgical Innovation, Technology and Evaluation Theme.

Urinary incontinence

Urinary incontinence is a debilitating medical condition that affects 8.5 percent of the global population. It can bring about a sense of loss of control and shame, leading to isolation and depression.

Charles Knowles, Chief Medical Officer of Amber TX and Professor of Surgery at Queen Mary University of London, states: “Urinary incontinence is one of the most common medical problems in humans. It causes misery for millions of men and women worldwide. Amber’s therapy represents the first advanced therapy directed to mixed urinary incontinence. Our study, to determine if this new treatment is safe, will be a major step forward in a field that has seen little real innovation for over a quarter of a century.”

Closed-loop neuromodulation

Amber Therapeutics uses its expertise in ‘closed-loop neuromodulation’ to transform clinical outcomes in patients with functional disorders of the peripheral nervous system. Closed-loop neuromodulation is a type of therapy that adjusts its stimulation parameters according to measurements of the nervous system’s needs in real time.

In the AURA-2 study, investigators are exploring how to directly regulate the urge to empty the bladder (‘urge incontinence’) while also increasing resistance to urine leakage caused by activities such as coughing or lifting (mixed urinary incontinence’).

The implanted device can sense, interpret, adapt and respond to individual patient commands in an attempt to restore normal bladder function. The device is inserted in participants’ pelvic region using a minimally invasive surgical procedure that accesses and targets the pudendal nerve – the nerve that directly controls continence.

Professor Tim Denison is Chief Scientific Officer of Amber Therapeutics and RAEng Chair in Emerging Technology at the Department of Engineering Science and Nuffield Department of Clinical Neurosciences at the University of Oxford. His research is supported by the Oxford BRC.

He said: “Modern bioelectronic systems have the unique capability to measure physiological signals and adjust stimulation in real-time. In partnership with clinicians, we can create novel adaptive, reflex-like, algorithms for exploring new therapies.

“The flexibility of these systems allows us to use software updates to configure to different disease states. The AURA-2 study builds on the prior trial in Multiple System Atrophy, and paves the way for emerging therapies in generalised epilepsy and chronic pain. We are grateful for our partnership and collaboration with Bioinduction, and their support of the state-of-the-art Picostim-DyNeuMo research system, which has allowed us to rapidly explore our first UI therapy concept.”

The clinical trial

To date, five participants have been safely implanted with the Amber-UI system with the adaptive algorithm activated and running continuously in a home setting. The remaining participants will be enrolled during the first half of 2023.

Early indications confirming the feasibility of the surgical procedure and therapy are very promising. The study is expected to conclude towards the end of 2023, with learnings used to improve and optimise the Amber-UI therapy in preparation for a large-scale trial.

Read more about this study.

← Oxford BRC researchers named NIHR Senior Investigators
Prostate cancer AI diagnosis tool begins evaluation in Oxford →

Other news

News Categories

News by Month

See all news

Subscribe to the Oxford BRC Newsletter

Keep informed about the work of the Oxford BRC by subscribing to our Mailchimp e-newsletter. It is produced several times a year and delivers news and information about upcoming events straight to your inbox.

Subscribe Now

Oxford BRC on Social Media

  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

Feedback

We’d love to hear your feedback. Please contact us at obrcenquiries@ouh.nhs.uk

  • Data Control and Privacy
  • Accessibility
  • Our Partners
  • Disclaimer
  • Contact

Copyright © 2023 NIHR Oxford Biomedical Research Centre